HC Wainwright Boosts BridgeBio Pharma (NASDAQ:BBIO) Price Target to $49.00

BridgeBio Pharma (NASDAQ:BBIO) had its price target increased by HC Wainwright from $43.00 to $49.00 in a research note issued to investors on Monday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for BridgeBio Pharma’s Q4 2024 earnings at ($0.99) EPS, FY2024 earnings at ($2.46) EPS, Q1 2025 earnings at ($0.83) EPS, Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($1.02) EPS and FY2025 earnings at ($3.72) EPS.

Several other analysts also recently issued reports on BBIO. Oppenheimer started coverage on BridgeBio Pharma in a research note on Thursday, October 3rd. They set a “market perform” rating for the company. JPMorgan Chase & Co. lowered their target price on BridgeBio Pharma from $46.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. Scotiabank raised their target price on BridgeBio Pharma from $44.00 to $45.00 and gave the stock a “sector outperform” rating in a report on Friday, November 15th. Leerink Partners dropped their target price on shares of BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Finally, Piper Sandler assumed coverage on shares of BridgeBio Pharma in a research note on Wednesday, September 4th. They set an “overweight” rating and a $46.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.43.

BridgeBio Pharma Trading Up 4.0 %

Shares of BridgeBio Pharma stock opened at $27.49 on Monday. BridgeBio Pharma has a 52 week low of $21.62 and a 52 week high of $44.32. The company’s 50-day moving average price is $25.01 and its two-hundred day moving average price is $26.22. The stock has a market cap of $5.20 billion, a PE ratio of -11.41 and a beta of 1.09.

Insider Buying and Selling at BridgeBio Pharma

In related news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $25.75, for a total transaction of $149,350,000.00. Following the completion of the sale, the insider now directly owns 25,260,971 shares in the company, valued at $650,470,003.25. This represents a 18.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Neil Kumar sold 27,389 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total transaction of $613,787.49. Following the completion of the transaction, the chief executive officer now directly owns 4,897,443 shares in the company, valued at approximately $109,751,697.63. The trade was a 0.56 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,831,545 shares of company stock valued at $150,056,923 over the last ninety days. 24.66% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BridgeBio Pharma

Institutional investors have recently added to or reduced their stakes in the business. Bfsg LLC boosted its position in BridgeBio Pharma by 175.6% in the second quarter. Bfsg LLC now owns 1,240 shares of the company’s stock valued at $31,000 after buying an additional 790 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of BridgeBio Pharma in the second quarter valued at about $48,000. Values First Advisors Inc. acquired a new stake in shares of BridgeBio Pharma during the 3rd quarter worth about $57,000. CWM LLC boosted its position in shares of BridgeBio Pharma by 132.9% during the third quarter. CWM LLC now owns 3,442 shares of the company’s stock worth $88,000 after buying an additional 1,964 shares during the period. Finally, Advisors Asset Management Inc. boosted its position in BridgeBio Pharma by 56.1% in the 3rd quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock valued at $117,000 after buying an additional 1,645 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.